Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Summary
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.
Description
This is an open-label, Phase I study of intravitreally administered ranibizumab in subjects with unresolving CSC and subfoveal fluid. Patients will be evaluated at baseline with ophthalmic examination, fluorescein angiography, optical coherence tomography, and color photography. Subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered every 28 days (± 2 days) for 3 injections. Thereafter they are to be evaluated every month until month 12. Treatment will be administered to patients if there is presence of active leakage as determined by fluorescein angiography or persistence presence of sub retinal fluid upon OCT examination at that monthly visit.
Study Design
Allocation: Non-Randomized, Control: Active Control, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Conditions
Central Serous Chorioretinopathy
Intervention
rhuFab V2 [ranibizumab] ( Lucentis )
Location
Vitreous Retina Macula Consultants of New York, P.C.
New York
New York
United States
10022
Status
Completed
Source
Vitreous -Retina- Macula Consultants of New York
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00403325
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-07-23T21:34:35-0400
Clinical Trials
Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy
Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy
Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy
The purpose of this clinical study is to evaluate the efficacy and safety of selective retina therapy (SRT) using R:GEN, an approved laser device, in patients with central serous chorioret...
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the...
Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed “idiopathic detachment of the macula” in 1866, is a well-characterized disor...
Treatment Trial for Acute Central Serous Chorioretinopathy
Central serous chorioretinopathy (CSC) is a relatively frequent eye disease in younger patients. It is characterized by serous detachment of the neurosensory retina with or without serous ...
PubMed Articles
To clarify the distinct molecular pathogenesis of central serous chorioretinopathy (CSC) and pachychoroid neovasculopathy (PNV).
To evaluate the changes in subfoveal retinal, and choroidal thicknesses (CT) in the non-treated acute and the ranibizumab-treated chronic central serous chorioretinopathy (CSCR) patients.This retrospe...
Clinical characteristics of pachydrusen in central serous chorioretinopathy.
To evaluate the clinical characteristics of pachydrusen in central serous chorioretinopathy (CSC) and investigate the relationship between choroidal circulation and pachydrusen.
Optical coherence tomography in diagnostics and treatment of central serous chorioretinopathy.
To identify the signs of leakage points in central serous chorioretinopathy (CSC) patients using optical coherence tomography (OCT) allowing focal laser photocoagulation (FLP) to be performed without ...
To evaluate early treatment outcomes of half-time photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSC).
Medical and Biotech [MESH] Definitions
Central Serous Chorioretinopathy
A visual impairment characterized by the accumulation of fluid under the retina through a defect in the retinal pigment epithelium.
Histiocytes
Macrophages found in the TISSUES, as opposed to those found in the blood (MONOCYTES) or serous cavities (SEROUS MEMBRANE).
Submandibular Gland
One of two salivary glands in the neck, located in the space bound by the two bellies of the digastric muscle and the angle of the mandible. It discharges through the submandibular duct. The secretory units are predominantly serous although a few mucous alveoli, some with serous demilunes, occur. (Stedman, 25th ed)
Ranibizumab
A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
Serous Membrane
A thin lining of closed cavities of the body, consisting of a single layer of squamous epithelial cells (MESOTHELIUM) resting on a thin layer of CONNECTIVE TISSUE, and covered with secreted clear fluid from blood and lymph vessels. Major serous membranes in the body include PERICARDIUM; PERITONEUM; and PLEURA.
